-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2024-510635-21-00
5
2023-05-09
warm autoimmune haemolytic anaemia (wAIHA)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2024-515830-34-00
5
2023-02-14
Congenital antithrombin deficiency
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2024-520006-19-00
6
2021-12-15
Non-muscle invasive bladder cancer
-
2023-506145-38-00
3
2021-05-11
Treatment of participants with MF, MDS, ET, or MDS/MPN
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-522979-29-00
5
2026-04-30
Acute myeloid leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523864-19-00
4
2026-04-23
Essential Thrombocythemia
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2023-509220-17-00
7
2026-04-10
Metastatic solid tumors
-
2025-522509-39-00
4
2026-03-30
Patients with myelofibrosis and platelets counts between 50 - 120 x 10
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-521670-34-00
5
2026-03-04
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
-
2025-522421-36-00
6
2026-02-27
Acute coronary syndrome
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521849-25-00
4
2026-02-17
Chronic Graft-Versus-Host Disease
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.